Canada OKs Orthometrix' shock wave therapy
This article was originally published in Clinica
Orthometrix has received approval in Canada to sell its high-energy shock wave system for treating plantar fasciitis (foot pain). The Orbasone device, a small and compact product, creates shock waves by using a spark plug enclosed in a soft membrane-covered dome filled with water; the dome is placed against the heel. The physician-supervised treatment typically takes about 30-40 minutes. Orbasone is manufactured in the US by Kimchuk, of Danbury, Connecticut, and distributed in Canada by Orthometrix. The product is already available in Europe and Asia, but has yet to be approved in the US, where Orthometrix is working towards completing its premarket approval (PMA) process with the FDA.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.